RYA W. ZOBEL, District Judge.
Plaintiff Blair Hamrick brought this suit under the anti-retaliation provision of the False Claims Act ("FCA"), 31 U.S.C. § 3730(h), for his termination from employment at the defendant GlaxoSmithKline ("GSK"). GSK has moved for summary judgment.
Plaintiff spills much ink recounting his long and difficult history at the company, including various perceived and actual slights and mistreatment, all of which is irrelevant to the present cause of action. The essential facts for this opinion follow, taken from the undisputed record.
Blair Hamrick began work at GSK as a pharmaceutical sales representative in Colorado in 1997. On January 30, 2002, plaintiff met with a GSK Compliance Officer to discuss plaintiff's allegations regarding off-label drug presentations sponsored by GSK.
On October 19, 2003, Hamrick was cited for driving under the influence of alcohol ("DUI"). On October 24, 2003, he voluntarily took a medical leave of absence because of anxiety and symptoms of post-traumatic stress disorder. On January 22, 2004, Hamrick pled guilty to driving while alcohol impaired ("DWAI") in connection with the October 2003 DUI citation.
Plaintiff returned to work on January 27, 2004, in his then current position as Senior Executive Sales Representative. On January 29, he had a call with Gail Fletcher and Claudia Pattison, managers in the Human Resources Department ("HR"), concerning his allegations of off-label drug presentations. On February 12, he met with Pattison to continue discussing his concerns regarding off-label drug presentations.
During the February 12, 2004, meeting with Pattison, plaintiff expressed anger towards his co-worker Peter Copeland, saying that he "would never do this, but ... [Peter] is lucky I don't rip his trachea out of his throat." Pattison was particularly concerned about this violent ideation, as she was aware Hamrick in fact carried a gun.
On March 16, 2004, Hamrick attended a GSK conference in Dallas, Texas. During the conference, while under the influence of prescription anti-anxiety medications and alcohol, he made several threats of violence against GSK managers. Three GSK employees reported plaintiff stating, and plaintiff does not dispute stating, the following:
Pursuant to that policy, Hamrick was immediately placed on administrative leave with pay pending an investigation into his statements in Dallas.
During this administrative leave, GSK became aware of Hamrick's DUI citation and DWAI conviction through its annual motor vehicle record check of those who, like Hamrick, possessed company-owned vehicles. He had not reported either occurrence to GSK, in violation of company policy.
In light of the reason for Hamrick's leave, GSK requested he undergo a fitness for duty ("FFD") evaluation on April 2, 2014, with an understanding by Hamrick that refusal to undergo the FFD would be grounds for termination. In response to this request, Hamrick provided a letter from his own psychiatrist, Dr. Crandall, stating her opinion that Hamrick is capable of performing his job responsibilities at GSK. Doctor Crandall had not evaluated Hamrick since his violent threats.
On April 19, plaintiff sent GSK a request for severance. On June 2, GSK responded with a counter-offer, and on June 6, plaintiff rejected the counter-offer and stated that he no longer wished to resign.
GSK's then Director of HR, Bill Reedy, scheduled a meeting with Hamrick on June 23 to discuss Hamrick's allegations about off-label marketing and his violations of policy (his driving offense and his threats of violence). Hamrick was informed that, per company policy, he could be accompanied by his attorney when GSK's attorneys were present during the meeting, but not during the HR portion of the meeting when no GSK attorneys would be present, which would cover his conduct issues.
On June 22, Hamrick's attorney, Keith Cross, informed Mr. Reedy that Hamrick would not meet with GSK without his attorney present. Due to this refusal, the meeting was cancelled. On September 1, GSK's outside counsel, Geoffrey Hobart, sent Cross a letter concerning Hamrick's refusal to meet with GSK, and explained that Hamrick was bound by GSK's Code of Conduct, and that "failure to fully cooperate with an investigation of an incident that occurs in the workplace" would be a further violation of company policy, potentially subjecting Mr. Hamrick to termination.
There followed a series of communications between counsel for the parties. On September 3, Cross responded, setting multiple conditions and terms of any meeting between Hamrick and GSK. On September 20, Hobart reiterated the company's request for an investigatory meeting and again stated that Cross could attend the portions of the meeting regarding off-label marketing but not those portions solely concerning the HR investigation of Hamrick's threats and unreported driving infraction. On September 24, Cross informed Hobart that plaintiff would not meet with GSK. On October 13, GSK informed Hamrick, through his attorney, that he had been terminated due to his threatening and violent statements regarding GSK employees, his failure to report his DUI citation and DWAI conviction, and his refusal to cooperate with GSK's investigation.
Summary judgment is appropriate when the moving party shows that there is no genuine dispute of material fact and the movant is entitled to judgment as a matter of law. Fed. R. Civ. P. 56(c). In considering whether or not a genuine issue of material fact exists, the court "must view the evidence in the light most favorable to the opposing party."
The burden in this case is on the plaintiff to show (i) that he was engaged in conduct protected under the FCA; (ii) the employer had knowledge of this conduct; and (iii) the employer retaliated against the employee because of this conduct."
The standard for this case is laid out in the First Circuit's decision in
There is no dispute that Hamrick was engaged in protected activity and that GSK was aware of that activity from as early as 2002. The decision to terminate Hamrick came only shortly after implicit confirmation to GSK that he was, in fact, a qui tam relator. This temporal proximity is, perhaps, sufficient to give an inference of animus, so I assume, without deciding, that plaintiff's prima facie burden was met.
Defendant provides a substantial non-retaliatory basis for its decision to terminate Hamrick, linked to three main things. First, the company cites Hamrick's erratic behavior and verbal threats made before and during a company retreat in March 2004. Second, it points out Hamrick's failure to disclose to the company his conviction of DWAI, in contravention of company policy requiring its disclosure. Third, GSK notes that company policy requires the termination of employees who refuse to cooperate with internal investigations, and defendant's refusal to fully comply with GSK's investigation into his erratic behavior and fitness for duty, by setting conditions to his meeting with the company. These events, taken together, are more than enough to shift the burden back to plaintiff.
The remaining question is whether plaintiff can point to sufficient evidence to allow a reasonable jury to find that, but for his protected whistleblowing activity, he would not have been terminated. Plaintiff is right that he may, to some extent, rely on timing-driven inference to make out his case for retaliation to a jury.
Defendant's motion for summary judgment is ALLOWED.
Judgment may be entered for the defendant.